Cited by 131Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement DisordersNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 156 of the 157 references it cites were found in a registry or an index.

Serotonin–dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias

CARTA, M, CARLSSON, T, MUNOZ, A, KIRIK, D, BJORKLUND, A·2008·Progress in brain research

DOI 10.1016/s0079-6123(08)00922-9

Open this paper in CoChat — free account

Abstract

Appearance of dyskinesia is a common problem of long-term Levodopa (L-DOPA) treatment in Parkinson's disease (PD) patients and represents a major limitation for the pharmacological management of the motor symptoms in the advanced stages of disease. An increasing body of evidence points to dopamine released as a false neurotransmitter from the striatal serotonin terminals as the main pre-synaptic determinant of L-DOPA-induced dyskinesia. Here we review the animal experimental and human clinical data in support of this view, which point to the serotonin system as a promising target for anti-dyskinetic therapy in PD patients under L-DOPA medication.

Integrity signals

Registry

Crossref · 10.1016/s0079-6123(08)00922-9

Cites

156 of 156 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Parkinson disease
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals
Steinbusch, H. W. M. (1981) · Neuroscience · doi:10.1016/0306-4522(81)90146-9 · Cited by 2,415
Molecular, pharmacological and functional diversity of 5-HT receptors
Hoyer, D., Hannon, J. P., & Martin, G. R. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00746-8 · Cited by 1,898
Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature
Ahlskog, J. E., & Muenter, M. D. (2001) · Movement Disorders · doi:10.1002/mds.1090 · Cited by 1,456
Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years
Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005) · Movement Disorders · doi:10.1002/mds.20324 · Cited by 1,050
Description of Parkinson's Disease as a Clinical Syndrome
Fahn, S. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07458.x · Cited by 979
Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey
Langston, J. W., Forno, L. S., Rebert, C. S., & Irwin, I. (1984) · Brain Research · doi:10.1016/0006-8993(84)90777-7 · Cited by 922
Dopamine-mediated regulation of corticostriatal synaptic plasticity
Calabresi, P., Picconi, B., Tozzi, A., & Di Filippo, M. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.001 · Cited by 865
Electrophysiological responses of serotoninergic dorsal raphe neurons to 5‐HT1A and 5‐HT1B agonists
Sprouse, J. S., & Aghajanian, G. K. (1987) · Synapse · doi:10.1002/syn.890010103 · Cited by 848
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia
Picconi, B., Centonze, D., Håkansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M. A., & Calabresi, P. (2003) · Nature Neuroscience · doi:10.1038/nn1040 · Cited by 821

Show all 157 references

Sorted by citations

Functional Neuroanatomy of the Basal GangliaPreprint
Lanciego, J. L., Luquin, N., & Obeso, J. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009621 · Cited by 848
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P., Feyder, M. T., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 492
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap
Calabresi, P., Filippo, M. D., Ghiglieri, V., Tambasco, N., & Picconi, B. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70218-0 · Cited by 398
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 333
Genetic Inactivation of Dopamine D1 but Not D2 Receptors Inhibits L-DOPA–Induced Dyskinesia and Histone Activation
Darmopil, S., Martín, A. B., Ruiz‐DeDiego, I., Ares‐Santos, S., & Moratalla, R. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.025 · Cited by 267
The serotonergic system in Parkinson's disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.004 · Cited by 195
α6β2* and α4β2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson’s Disease
Quik, M., & Wonnacott, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003269 · Cited by 201
Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease
Navailles, S., Bioulac, B. H., Gross, C. E., & Deurwaerdère, P. D. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.01.012 · Cited by 187
Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies
Kwon, D. K., Kwatra, M., Wang, J., & Ko, H. S. (2022) · Cells · doi:10.3390/cells11233736 · Cited by 175
Serotonergic modulation of the activity of mesencephalic dopaminergic systems: Therapeutic implications
Deurwaerdère, P. D., & Giovanni, G. D. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.004 · Cited by 170
Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations
Huot, P., Johnston, T. H., Darr, T., Hazrati, L., Visanji, N. P., Pires, D., Brotchie, J. M., & Fox, S. H. (2010) · Movement Disorders · doi:10.1002/mds.23083 · Cited by 153
Multiple roles for nicotine in Parkinson's disease
Quik, M., Huang, L. Z., Parameswaran, N., Bordia, T., Campos, C., & Perez, X. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.003 · Cited by 137
Levodopa-induced plasticity: a double-edged sword in Parkinson's disease?
Calabresi, P., Ghiglieri, V., Mazzocchetti, P., Corbelli, I., & Picconi, B. (2015) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2014.0184 · Cited by 119
High-Frequency Stimulation of the Subthalamic Nucleus and l-3,4-Dihydroxyphenylalanine InhibitIn VivoSerotonin Release in the Prefrontal Cortex and Hippocampus in a Rat Model of Parkinson's Disease
Navailles, S., Benazzouz, A., Bioulac, B. H., Gross, C. E., & Deurwaerdère, P. D. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.5031-09.2010 · Cited by 106
Serotonin and dopamine striatal innervation in Parkinson’s disease and Huntington’s chorea
Bédard, C., Wallman, M., Pourcher, E., Gould, P. V., Parent, A., & Parent, M. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.05.012 · Cited by 103
Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease
Navailles, S., Bioulac, B. H., Gross, C. E., & Deurwaerdère, P. D. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.11.007 · Cited by 102
5-HT1AReceptor: An Old Target as a New Attractive Tool in Drug Discovery from Central Nervous System to Cancer
Fiorino, F., Severino, B., Magli, E., Ciano, A., Caliendo, G., Santagada, V., Frecentese, F., & Perissutti, E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400533t · Cited by 90
Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat
Jaunarajs, K. L. E., Dupre, K. B., Ostock, C. Y., Button, T., Terrence Deak, B., & Bishop, C. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833e7e80 · Cited by 87
Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression
Riederer, P. F., Strobel, S., Nagatsu, T., Watanabe, H., Chen, X. M., Löschmann, P. A., Sian‐Hülsmann, J., Jost, W. H., Müller, T. H., Dijkstra, J. M., et al. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02893-4 · Cited by 96
Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders
Newman‐Tancredi, A., Depoortère, R., Kleven, M. S., Kołaczkowski, M., & Zimmer, L. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107937 · Cited by 83
Immediate-early gene expression in structures outside the basal ganglia is associated to l-DOPA-induced dyskinesia
Bastide, M. F., Doveró, S., Charron, G., Porras, G., Gross, C. E., Fernagut, P., & Bézard, E. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.020 · Cited by 82
Nicotinic receptor-mediated reduction in l-DOPA-induced dyskinesias may occur via desensitization
Bordia, T., Campos, C., McIntosh, J. M., & Quik, M. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162396 · Cited by 82
The serotonergic system in motor and non-motor manifestations of Parkinson’s disease
Huot, P., & Fox, S. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3621-2 · Cited by 83
Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson’s Disease and Adverse Effects of L-DOPA
Muñoz, A., López-López, A., Labandeira, C. M., & Labandeira-García, J. L. (2020) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2020.00026 · Cited by 82
Serotonin System Implication in l-DOPA-Induced Dyskinesia: From Animal Models to Clinical Investigations
Carta, M., & Tronci, E. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00078 · Cited by 72
Functional correlates of exaggerated oscillatory activity in basal ganglia output in hemiparkinsonian rats
Brazhnik, E. S., Novikov, N., McCoy, A. J., Cruz, A. V., & Walters, J. R. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.07.010 · Cited by 63
Nicotine reduces established levodopa‐induced dyskinesias in a monkey model of Parkinson's disease
Quik, M., Mallela, A., Ly, J., & Zhang, D. (2013) · Movement Disorders · doi:10.1002/mds.25594 · Cited by 60
Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms
Ghiglieri, V., Mineo, D., Vannelli, A., Cacace, F., Mancini, M., Pendolino, V., Napolitano, F., di Maio, A., Mellone, M., Stanic, J., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.11.022 · Cited by 58
3D Fuzzy Graphene Microelectrode Array for Neurotransmitter Sensing at Sub-cellular Spatial Resolution
Castagnola, E., Garg, R., Rastogi, S. K., Cohen‐Karni, T., & Cui, X. T. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113440 · Cited by 56
Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies
Sharma, S., Singh, S., Sharma, V., Singh, V. P., & Deshmukh, R. R. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.01.029 · Cited by 60
Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence
Bandopadhyay, R., Mishra, N., Rana, R., Kaur, G., Ghoneim, M. M., Alshehri, S., Mustafa, G., Ahmad, J., Alhakamy, N. A., & Mishra, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.805388 · Cited by 58
Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease
Schaeffer, E., Pilotto, A., & Berg, D. (2014) · CNS Drugs · doi:10.1007/s40263-014-0205-z · Cited by 54
Nondopaminergic Treatments for Parkinson’s Disease: Current and Future Prospects
Freitas, M. E., & Fox, S. H. (2016) · Neurodegenerative Disease Management · doi:10.2217/nmt-2016-0005 · Cited by 53
Multisite Intracerebral Microdialysis to Study the Mechanism of L-DOPA Induced Dopamine and Serotonin Release in the Parkinsonian Brain
Navailles, S., Lagière, M., Contini, A., & Deurwaerdère, P. D. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400046e · Cited by 52
Cell Transplantation and Gene Therapy in Parkinson's Disease
Wakeman, D. R., Dodiya, H. B., & Kordower, J. H. (2011) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20233 · Cited by 52
5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA
Huot, P., Johnston, T. H., Winkelmolen, L., Fox, S. H., & Brotchie, J. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.035 · Cited by 50
The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets
Fisher, R., Hikima, A., Morris, R. H., Jackson, M. J., Rose, S., Varney, M. A., Depoortère, R., & Newman‐Tancredi, A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107997 · Cited by 50
Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals
Lohr, K. M., Chen, M., Hoffman, C. A., McDaniel, M. J., Stout, K. A., Dunn, A. R., Wang, M., Bernstein, A. I., & Miller, G. W. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw106 · Cited by 48
Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia
Bézard, E., Muñoz, A., Tronci, E., Pioli, E. Y., Li, Q., Porras, G., Björklund, A., & Carta, M. (2013) · Neuroscience Research · doi:10.1016/j.neures.2013.10.002 · Cited by 47
Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia
Navailles, S., & Deurwaerdère, P. D. (2011) · Parkinson s Disease · doi:10.1155/2012/323686 · Cited by 47
S100B Transgenic Mice Develop Features of Parkinson's Disease
Liu, J., Wang, H., Zhang, L., Xu, Y., Deng, W., Zhu, H., & Qin, C. (2011) · Archives of Medical Research · doi:10.1016/j.arcmed.2011.01.005 · Cited by 46
Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives
Jamebozorgi, K., Taghizadeh, E., Rostami, D., Pormasoumi, H., Barreto, G. E., Hayat, S. M. G., & Sahebkar, A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1419-8 · Cited by 46
ABT‐089 and ABT‐894 reduce levodopa‐induced dyskinesias in a monkey model of Parkinson's disease
Zhang, D., Bordia, T., McGregor, M. M., McIntosh, J. M., Decker, M. W., & Quik, M. (2014) · Movement Disorders · doi:10.1002/mds.25817 · Cited by 45
Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with l-DOPA
Dominguez‐Meijide, A., Villar‐Cheda, B., Garrido‐Gil, P., Sierrra-Paredes, G., Guerra, M. J., & Labandeira-García, J. L. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.016 · Cited by 46
Nicotine-mediated improvement in l-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function
Quik, M., Mallela, A., Chin, M. C., McIntosh, J. M., Perez, X. A., & Bordia, T. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.09.006 · Cited by 45
Serotonin hyperinnervation of the striatum with high synaptic incidence in parkinsonian monkeys
Gagnon, D., Grégoire, L., Paolo, T. D., & Parent, M. (2015) · Brain Structure and Function · doi:10.1007/s00429-015-1125-5 · Cited by 44
Anatomically Selective Serotonergic Type 1A and Serotonergic Type 2A Therapies for Parkinson’s Disease: An Approach to Reducing Dyskinesia without Exacerbating Parkinsonism?
Huot, P., Fox, S. H., Newman‐Tancredi, A., & Brotchie, J. M. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.184093 · Cited by 44
α4β2 nicotinic receptors play a role in the nAChR-mediated decline in l-dopa-induced dyskinesias in parkinsonian rats
Quik, M., Campos, C., Bordia, T., Strachan, J., Zhang, J., McIntosh, J. M., Letchworth, S. R., & Green-Jordan, K. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.038 · Cited by 43
Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque
Huot, P., Johnston, T. H., Koprich, J. B., Winkelmolen, L., Fox, S. H., & Brotchie, J. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.09.011 · Cited by 43
The Monoamine Re-Uptake Inhibitor UWA-101 Improves Motor Fluctuations in the MPTP-Lesioned Common Marmoset
Huot, P., Johnston, T. H., Gandy, M. N., Reyes, M. G., Fox, S. H., Piggott, M., & Brotchie, J. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045587 · Cited by 40
Is there a role for ghrelin in central dopaminergic systems? Focus on nigrostriatal and mesocorticolimbic pathways
Stievenard, A., Méquinion, M., Andrews, Z. B., Destée, A., Chartier-Harlin, M.-C., Viltart, O., & Vanbesien-Mailliot, C. C. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.11.021 · Cited by 39
Monoamine Reuptake Inhibitors in Parkinson’s Disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2015) · Parkinson s Disease · doi:10.1155/2015/609428 · Cited by 43
Cell-Based Therapies for Parkinson's Disease: Past, Present, and Future
Fitzpatrick, K. M., Raschke, J., & Emborg, M. E. (2009) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2654 · Cited by 38
The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques
Depoortère, R., Johnston, T. H., Fox, S. H., Brotchie, J. M., & Newman‐Tancredi, A. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.08.009 · Cited by 37
Targeting Nicotinic Receptors for Parkinson's Disease Therapy
Quik, M., Bordia, T., Huang, L. Z., & Perez, X. A. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711797247849 · Cited by 38
Da-Bu-Yin-Wan and Qian-Zheng-San, two traditional Chinese herbal formulas, up-regulate the expression of mitochondrial subunit NADH dehydrogenase 1 synergistically in the mice model of Parkinson's disease
Zhang, Y., Sun, H., He, X., Wang, Y., Gao, Y.-S., Wu, H.-X., Xu, H., Gong, X., & Guo, Z. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.01.005 · Cited by 36
Mathematical Insights into the Effects of Levodopa
Reed, M. C., Nijhout, H. F., & Best, J. A. (2012) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2012.00021 · Cited by 35
Serotonergic involvement in levodopa-induced dyskinesias in Parkinson’s disease
Cheshire, P., & Williams, D. R. (2012) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2011.09.008 · Cited by 33
Synthesis, biological evaluation and molecular modeling of 1-oxa-4-thiaspiro- and 1,4-dithiaspiro[4.5]decane derivatives as potent and selective 5-HT1A receptor agonists
Franchini, S., Manasieva, L. I., Sorbi, C., Battisti, U. M., Fossa, P., Cichero, E., Denora, N., Iacobazzi, R. M., Cilia, A., Pirona, L., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.050 · Cited by 33
Depression in Parkinson's disease
Ossowska, K., & Lorenc‐Koci, E. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71516-0 · Cited by 31
Neuroimaging Over the Course of Parkinson's Disease: From Early Detection of the At-Risk Patient to Improving Pharmacotherapy of Later-Stage Disease
Seibyl, J. P., Russell, D., Jennings, D. L., & MAREK, K. L. (2012) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2012.06.003 · Cited by 28
Monoamine Levels and Parkinson’s Disease Progression: Evidence From a High-Performance Liquid Chromatography Study
Wichit, P., Thanprasertsuk, S., Phokaewvarangkul, O., Bhidayasiri, R., & Bongsebandhu‐phubhakdi, S. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.605887 · Cited by 27
Serotonin/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: An update
Corsi, S., Stancampiano, R., & Carta, M. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.01.032 · Cited by 27
The Parkinson's disease death rate: carbidopa and vitamin B6
Hinz, M., Stein, A. L., & Cole, T. (2014) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s70707 · Cited by 25
Retracted
Age-Dependent Maintenance of Motor Controland Corticostriatal Innervation by Death Receptor 3
Twohig, J. P., Roberts, M. I., Gavaldà, N., Rees-Taylor, E. L., Giralt, A., Adams, D., Brooks, S. P., Bull, M. J., Calder, C. J., Cuff, S. M., et al. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1928-09.2010 · Cited by 23
Neuroplasticity in levodopa-induced dyskinesias: An overview on pathophysiology and therapeutic targets
Bove, F., Angeloni, B. M., Sanginario, P., Rossini, P. M., Calabresi, P., & Iorio, R. D. (2023) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2023.102548 · Cited by 24
Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications
Miguélez, C., Benazzouz, A., Ugedo, L., & Deurwaerdère, P. D. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00274 · Cited by 22
Serotonergic modulation of basal ganglia circuits
Benarroch, E. E. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b784e7 · Cited by 21
Anti-dyskinetic efficacy of 5-HT3 receptor antagonist in the hemi-parkinsonian rat model
Aboulghasemi, N., Jahromy, M. H., & Ghasemi, A. (2018) · IBRO Reports · doi:10.1016/j.ibror.2018.12.001 · Cited by 20
Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update
Alshimemeri, S. A., Fox, S. H., & Visanji, N. P. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1763954 · Cited by 20
A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease
Ko, W. K. D., Li, Q., Cheng, L., Morelli, M., Carta, M., & Bézard, E. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.07.030 · Cited by 19
Parkinson's disease: carbidopa, nausea, and dyskinesia
Hinz, M., Stein, A. L., & Cole, T. (2014) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s72234 · Cited by 17
Retracted
NLX ‐112 Randomized Phase 2A Trial: Safety, Tolerability, Anti‐Dyskinetic, and Anti‐Parkinsonian Efficacy
Svenningsson, P., Odin, P., Bergquist, F., Wirdefeldt, K., Nyholm, D., Andréasson, M., Markaki, I., Johansson, A., Jergil, M., Jankosky, C., et al. (2025) · Movement Disorders · doi:10.1002/mds.30175 · Cited by 16
l-DOPA- and graft-induced dyskinesia following transplantation
Lane, E. L., & Winkler, C. (2012) · Progress in brain research · doi:10.1016/b978-0-444-59575-1.00007-7 · Cited by 17
Cannabis exposure during adolescence: A uniquely sensitive period for neurobiological effects
Peters, K. Z., Zlebnik, N. E., & Cheer, J. F. (2021) · International review of neurobiology · doi:10.1016/bs.irn.2021.07.002 · Cited by 20
Inhibiting Lateral Habenula Improves L-DOPA–Induced Dyskinesia
Bastide, M. F., de la Crompe, B., Doudnikoff, É., Fernagut, P., Gross, C. E., Mallet, N. P., Boraud, T., & Bézard, E. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.08.022 · Cited by 16
Serotonin as a biomarker of toxin-induced Parkinsonism
Buchanan, A. M., Mena, S., Choukari, I., Vasa, A., Crawford, J., Fadel, J. R., Maxwell, N., Reagan, L. P., Cruikshank, A. E., Best, J. A., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-023-00773-9 · Cited by 15
Interactions between Angiotensin Type-1 Antagonists, Statins, and ROCK Inhibitors in a Rat Model of L-DOPA-Induced Dyskinesia
López-López, A., Valenzuela, R., Rodriguez-Perez, A. I., Guerra, M. J., Labandeira-García, J. L., & Muñoz, A. (2023) · Antioxidants · doi:10.3390/antiox12071454 · Cited by 14
5-HT1A receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: Bridging the gap between serotonergic and glutamatergic mechanisms
Huot, P., & Brotchie, J. M. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.07.006 · Cited by 14
5-HT(1A) receptor activation improves anti-cataleptic effects of levodopa in 6-hydroxydopamine-lesioned rats.
Mahmoudi, J., Nayebi, A. M., Samini, M., Reyhani‐Rad, S., & Babapour, V. (2011) · Europe PMC (PubMed Central) · Cited by 14
Imaging DA release in a rat model of L-DOPA-induced dyskinesias: A longitudinal in vivo PET investigation of the antidyskinetic effect of MDMA
Lettfuss, N. Y., Fischer, K., Sossi, V., Pichler, B., & von Ameln-Mayerhofer, A. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.06.051 · Cited by 13
Synaptic Interactions Between Serotonergic and Dopaminergic Systems in Parkinson’s Disease
Marino, G., Campanelli, F., Natale, G., Carluccio, M. D., Servillo, F., Ghiglieri, V., & Calabresi, P. (2025) · Current Neuropharmacology · doi:10.2174/011570159x336597241217062042 · Cited by 14
Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats
Mahmoudi, J., Nayebi, A. M., Samini, M., Reyhani‐Rad, S., & Babapour, V. (2011) · Pharmacological Reports · doi:10.1016/s1734-1140(11)70606-5 · Cited by 13
Fluoxetine Improves the Effect of Levodopa on 6-Hydroxy Dopamine-Induced Motor Impairments in Rats
Mahmoudi, J., Nayebi, A. M., Reyhani-Rad, S., & Samini, M. (2012) · Europe PMC (PubMed Central) · doi:10.5681/apb.2012.023 · Cited by 13
5-Hydroxytryptophan Reduces Levodopa-Induced Dyskinesia via Regulating AKT/mTOR/S6K and CREB/ΔFosB Signals in a Mouse Model of Parkinson’s Disease
Choi, Y., Huh, E., Lee, S.-M., Kim, J. H., Park, M. G., Seo, S., Kim, S. Y., & Oh, M. S. (2023) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2022.141 · Cited by 12
Broad Serotonergic Actions of Vortioxetine as a Promising Avenue for the Treatment of L-DOPA-Induced Dyskinesia
Budrow, C., Elder, K. K., Coyle, M., Centner, A., Lipari, N., Cohen, S. R., Glinski, J., Kinzonzi, N., Wheelis, E., McManus, G., et al. (2023) · Cells · doi:10.3390/cells12060837 · Cited by 12
Understanding Graft-Induced Dyskinesia
Lane, E. L., & Smith, G. A. (2010) · Regenerative Medicine · doi:10.2217/rme.10.42 · Cited by 11
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys
Morin, N., Morissette, M., Grégoire, L., & Paolo, T. D. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.07.006 · Cited by 11
Serotonergic system modulation holds promise for L‐DOPA‐induced dyskinesias in hemiparkinsonian rats: A systematic review
Farajdokht, F., Sadigh‐Eteghad, S., Majdi, A., Pashazadeh, F., Vatandoust, S. M., Ziaee, M., Safari, F., Karimi, P., & Mahmoudi, J. (2020) · EXCLI journal · doi:10.17179/excli2020-1024 · Cited by 11
Clinical and Experimental Experiences of Graft-Induced Dyskinesia
Lane, E. L. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-381328-2.00007-9 · Cited by 10
L‐3,4‐dihydroxyphenylalanine‐induced sprouting of serotonin axon terminals: A useful biomarker for dyskinesias?
Picconi, B., Ghiglieri, V., & Calabresi, P. (2010) · Annals of Neurology · doi:10.1002/ana.22231 · Cited by 11
A Multi-Scale Computational Model of Levodopa-Induced Toxicity in Parkinson's Disease
Muddapu, V. R., Vijayakumar, K., Ramakrishnan, K., & Chakravarthy, V. S. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.797127 · Cited by 9
Plasticity, genetics, and epigenetics in l-dopa-induced dyskinesias
Bove, F., & Calabresi, P. (2022) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819410-2.00009-6 · Cited by 9
Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson’s Disease
Tseng, K.-Y., Kuo, T., Wang, V., Huang, E. Y., Ma, K., Olson, L., Hoffer, B. J., & Chen, Y.-H. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223195 · Cited by 8
Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease
Lipari, N., Centner, A., Glinski, J., Cohen, S. R., Manfredsson, F. P., & Bishop, C. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105965 · Cited by 8
Dorsal GPi/GPe Stimulation Induced Dyskinesia in a Patient with Parkinson’s Disease
Elkouzi, A., Tsuboi, T., Burns, M. R., Eisinger, R. S., Patel, A., & Deeb, W. (2019) · PubMed Central · doi:10.7916/tohm.v0.685 · Cited by 8
Functional Neuroanatomy of the Normal and Pathological Basal GangliaPreprint
Lanciego, J. L., & Obeso, J. A. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041617 · Cited by 8
Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease
Jenner, P. G., Falup‐Pecurariu, C., Leta, V., Vérin, M., Auffret, M., Bhidayasiri, R., Weiss, D., Borovečki, F., & Jost, W. H. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02655-0 · Cited by 8
Targeting Striatal Glutamate and Phosphodiesterases to Control L-DOPA-Induced Dyskinesia
Kochoian, B. A., Bure, C., & Papa, S. M. (2023) · Cells · doi:10.3390/cells12232754 · Cited by 8
Neuroinflammation and Dyskinesia: A Possible Causative Relationship?
Cardinale, A., de Iure, A., & Picconi, B. (2024) · Brain Sciences · doi:10.3390/brainsci14050514 · Cited by 8

Authors: CARTA, M., CARLSSON, T., MUNOZ, A., KIRIK, D., & BJORKLUND, A.
Affiliations: Lund University (SE)
Corresponding author: CARTA, M
ORCID: CARTA, M
CARLSSON, T
KIRIK, D
Venue: Progress in brain research
Publisher: Elsevier
Published: 2008
Volume: 172
Pages: 465-478
ISSN: 0079-6123 (ISSN-L)
DOI: 10.1016/s0079-6123(08)00922-9
OpenAlex: W1933235205
Cited by: 131
References: 157
Citations by year: 2026: 2 · 2025: 4 · 2024: 5 · 2023: 6 · 2022: 8 · 2021: 4 · 2020: 8 · 2019: 2 · 2018: 2 · 2017: 6 · 2016: 6 · 2015: 6 · 2014: 13 · 2013: 14 · 2012: 11
FWCI: 37.83
Type: book chapter
Language: en
Open access: closed
Locations: Progress in brain research (publishedVersion)
PubMed (publishedVersion)
UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
Lund University Publications (Lund University) (submittedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: serotonin, dopamine, levodopa-induced dyskinesia, Parkinson's disease, serotonergic system, serotonergic neurons, treatment options
MeSH terms: Animals, Clinical Trials as Topic, Dopamine, Dyskinesia, Drug-Induced, Humans, Levodopa, Parkinson Disease, Receptors, Dopamine, Receptors, Serotonin, Serotonin, Presynaptic Terminals, Protein Isoforms, Parkinsonian Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Serotonin–dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks